AMILOIDOZ SERDTsA: KLINIKA, LEChENIE, PROGNOZ


Cite item

Full Text

Open Access Open Access
Restricted Access Access granted
Restricted Access Subscription or Fee Access

Abstract

Cardiac amyloidosis (CA) is one of the most severe manifestations of systemic amyloidosis. The current classification of amyloidosis is based on differences of amyloidogenic precursor proteins. To date, there are about 30 such proteins; therefore, there are about 30 forms of amyloidosis. The article discusses the morphology and pathogenesis of amyloidosis, disturbances of cardiac function, and prognosis depending on the variant of amyloidosis, cardiac disorders, and blood levels of markers of cardiomyocyte damage, as well as depending on the presence and severity of extracardiac manifestations of amyloidosis. Treatment of systemic amyloidosis depending on the variant of the disease is presented.

Full Text

Restricted Access

References

  1. Kyle R, Rajkumar S. Treatment of multiple myeloma: a comprehensive review. Clin Lymphoma Myeloma 2009;9(4):278-88.
  2. Shah K, Inoue Y, Mehra M. Amyloidosis and the heart: a comprehensive review. Arch Intern Med 2006;66( 1 7):1805-13.
  3. Connors B, Davidoff R, Skinner M, Falk R. Senile systemic amyloidosis presenting with heart failure: A comparison with light chain-associated amyloidosis. Arch Intern Med 2005;165:1425-29.
  4. Kyle R, Gertz M. Primary systemic amyloidosis: clinical and laboratory features in 474 cases. Semin Hematol 1995;32(1):45-59.
  5. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-57.
  6. Steiner I. The prevalence of isolated atrial amyloid. J Pathol 1987;153(4):395-98.
  7. Rocken C, Peters B, Juenemann G, et al. Atrial amyloidosis: An arrhythmogenic substrate for persistent atrial fibrillation. Circulation 2002;106:2091-97.
  8. Ariyarajah P, Steiner I, Hajkova P, et al. The association of atrial tachyarrhythmias with isolated atrial amyloid disease: preliminary observations in autopsied heart specimens. Cardiology 2009:113(2):132-37.
  9. Steiner I, Hajkova P. Patterns of isolated atrial amyloid: a study of 100 hearts on autopsy. Cardiovasc Pathol 2006;15(5):287-90.
  10. Ando Y, Nakamura M, Araki S. Transthyretin-related familial amyloidotic polyneuropathy. Arch Neurol 2005;62:1057-62.
  11. Gillmore J, Booth D, Pepys M, Hawkins N. Hereditary cardiac amyloidosis associated with the transthyretin Ile122 mutation in a white man. Heart 1999;82:2.
  12. Stangou A, Banner N, Hendry B, et al. Hereditary fibrinogen A-chain amyloidosis: phenotypic characterization of a systemic disease and the role of liver transplantation. Blood 2010;115:2998-3007.
  13. Hamer M.J, Janssen S, Van Ruswuk M, Lie K. Amyloid cardiomyopathy in systemic non-hereditary amyloidosis. Clinical, echo-cardiographic and electrocardiographic findings in 30 patients with AA and 24 patients with AL amyloidosis. Eur Heart J 1992; 13:623-27.
  14. Ha S, Kim W, Hwang S, et al. A case of systemic amyloidosis following ankylosing spondylitis associated with congestive heart failure. J Am Soc Echocardiogr 2009;22(5):542-47.
  15. Frenzel H, Schwartzkopff B, Kuhn H, et al. Cardiac amyloid deposits in endomyocardial biopsies. Light microscopic, ultrastructural, and immunohistochemical studies. Am J Clin Pathol 1986;85(6):674-80.
  16. Rapezzi C, Merlini G, Quarta C.C, et al. Systemic cardiac amyloidoses: disease profiles and clinical courses of the 3 main types. Circulation 2009;120:1203-12.
  17. Sedlis S, Saffitz J, Schwob S, Jaffe A. Cardiac amyloidosis simulating hypertrophic cardiomyopathy. Am J Cardiol 1984;53:969-70.
  18. Dubrey S, Cha K, Anderson J, et al. The clinical features of immunoglobulin light-chain (AL) amyloidosis with heart involvement. QJM 1998;91:141-57.
  19. Siqueira-Filho A, Cunha C, Tajik A, et al. M-mode and two-dimensional echocar-diographic features in cardiac amyloidosis. Circulation 1981;63:188-96.
  20. Rapezzi C, Perugini E, Salvi F, et al. Phenotypic and genotypic heterogeneity in transthyretin-related cardiac amyloidosis: towards tailoring of therapeutic strategies? Amyloid 2006;13:143-53.
  21. Liao R, Jain M, Teller P, et al. Infusion of light chains from patients with cardiac amyloidosis causes diastolic dysfunction in isolated mouse hearts. Circulation 2001;104:1594.
  22. Shi J, Guan J, Jiang В, et al. Amyloidogenic light chains induce cardiomyocyte contractile dysfunction and apoptosis via a non-canonical p38 MAPK pathway. PNAS 2010; 107:4188-93.
  23. Truran S, Gutterman D, Schlundt B, et al. Oxidative stress and apoptotic injury induced by amyloidogenic light chain proteins in human coronary artery endothelial cells. Circulation 2010;122:16538.
  24. Perugini E, Rapezzi C, Piva T, et al. Noninvasive evaluation of the myocardial substrate of cardiac amyloidosis by gadolinium cardiac magnetic resonance. Heart 2006;92: 343-49.
  25. Takemura G, Takatsu Y, Doyama K, et al. Expression of atrial and brain natriuretic peptides and their genes in hearts of patients with cardiac amyloidosis. J Am Coll Cardiol 1998;31:754-65.
  26. Palladini G, Campana C, Klersy C, et al. Serum N-terminal pro-brain natriuretic peptide is a sensitive marker of myocardial dysfunction in AL amyloidosis. Circulation 2003;107: 2440-45.
  27. Hisaki R, Yutani C, Imakita M, et al. Histopathological study of valvular deposits of amyloid protein in cardiac amyloidosis. J Cardiol 1996;31:7.
  28. Vogelsberg H, Mahrholdt H, Deluigi C, et al. Cardiovascular magnetic resonance in clinically suspected cardiac amyloidosis: noninvasive imaging compared to endomyocardial biopsy. J Am Coll Cardiol 2008;51: 1022-30.
  29. Volpi A, Cavalli A, Maggioni A, et al. Cardiac amyloidosis involving the conduction sys tem and the aortocoronary neuroreceptors. Clinicopathologic. correlates. Chest 1986;90:619-21.
  30. Ishikawa Y, Ishii T, Masuda S, et al. Myocardial ischemia due to vascular systemic amyloidosis: a quantitative analysis of autopsy findings on stenosis of the intramural coronary arteries. Pathol Int 1996;46(3):189-94.
  31. Suwaidi J.A, Velianou J, Gertz M, et al. Systemic amyloidosis presenting with angina pectoris. Ann Intern Med 1999;131:838-41.
  32. Whitaker D, Tungekar M, Dussek J. Angina with a normal coronary angiogram caused by amyloidosis. Heart 2004;90:54.
  33. Perugini E, Guidalotti L, Salvi F, et al. Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J Am Coll Cardiol 2005;46:1076-84.
  34. Klein A, Hatle L, Taliercio C, et al. Serial Doppler echocardiographic follow-up of left ventricular diastolic function in cardiac amyloidosis. J Am Coll Cardiol 1990;16:1135-41.
  35. Demir M, Paydas S, Cayli M, et al. Tissue Doppler is a more reliable method in early detection of cardiac dysfunction in patients with AA amyloidosis. Ren Fail 2005; 27:415-20.
  36. Klein A, Hatle L, Taliercio C, et al. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808-16.
  37. Cueto-Garcia L, Tajik A, Kyle R, et al. Serial echocardiographic observations in patients with primary systemic amyloidosis: an introduction to the concept of early (asymptomatic) amyloid infiltration of the heart. Mayo Clin Proc 1984;59(9):589-97.
  38. Falk R. Diagnosis and management of the cardiac amyloidosis. Circulation 2005;112(13):2047-60.
  39. Feng Da Li, Edwards W, Oh J. Intracardiac thrombosis and embolism in patients with cardiac amyloidosis. Circulation 2007;116:2420-26.
  40. Gertz M, Comenzo R, Falk R. Definition of organ involvement and treatment response in primary systemic amyloidosis (AL): A consensus opinion from the 10th International Symposium on Amyloid and Amyloidosis. Blood (ASH Annual Meeting Abstracts) 2004;104:754.
  41. Klein A, Hatle L, Taliercio C. Prognostic significance of Doppler measures of diastolic function in cardiac amyloidosis. A Doppler echocardiography study. Circulation 1991;83:808-16.
  42. Kristen A, Perz J, Schonland S, Hegenbart U. Non-invasive predictors of survival in cardiac amyloidosis. Europ J Heart Failure 2007;9:617-24.
  43. Dispenzieri A, Kyle R, Gertz M, et al. Survival in patients with primary systemic amyloidosis and raised serum cardiac troponins. Lancet 2003;361:1787-89.
  44. Palladini G, Lavatelli F, Russo, et al. Circulating amyloidogenic free light chains and serum N-terminal natriuretic peptide type B decrease simultaneously in association with improvement of survival in AL. Blood 2006;107: 3854-58.
  45. Herlenius G, Wilczek H, Larsson M, Ericzon B. Ten years of international experience with liver transplantation for familial amyloidot-ic polyneuropathy: results from the Familial Amyloidotic Polyneuropathy World Transplant Registry. Transplantation 2004;77:64-71.
  46. Lewis W, Skinner M, Simms R, et al. Orthotopic liver transplantation for familial amyloid-otic polyneuropathy. Clin Transplant 1994; 8:107-10.
  47. Parrilla P, Ramirez P, Andreu L, et al. Long-term results of liver transplantation in familial amy-loidoticpolyneuropathytypeI. Transplantation 1997;64:646-49.
  48. Delahaye N, Rouzet F, Sarda L, et al. Impact of liver transplantation on cardiac autonomic denervation in familial amyloid polyneuropathy. Medicine (Baltimore) 2006; 85(4):229-38.
  49. Nardo B, Beltempo P, Bertelli R, et al. Combined heart and liver transplantation in four adults with familial amyloidosis: experience of a single center. Transplant Proc 2004;36:645-47.
  50. Selvanayagam J, Hawkins N, et al. Evaluation and management of the cardiac amyloidosis. J Am Coll Cardiol 2007;50:2101-10.
  51. Gertz M, Falk R, Skinner M, et al. Worsening of congestive heart failure in amyloid heart disease treated by calcium channelblocking agents. Am J Cardiol 1985;55(13):1645.
  52. Griffiths B, Hughes P, Dowdle R, et al. Cardiac amyloidosis with asymmetrical septal hypertrophy and deterioration after nifedipine. Thorax 1982;37:711-12.
  53. Rubinow A, Skinner M, Cohen A. Digoxin sensitivity in amyloid cardiomyopathy. Circulation idosis: two cases with digitalis sensitivity. Ann Intern Med 1961;55:989-94.
  54. Austin B, Duffy B, Tan C, et al. Comparison of functional status, electrocardiographic, and echocardiographic parameters to mortality in endomyocardial-biopsy proven cardiac amyloidosis. Am J Cardiol 2009; 103(10): 1429-33.
  55. Comenzo R. How I treat amyloidosis. Blood 2009;114:3147-57.
  56. Koch D, Sack F, Kristen A, et al. Treatment options for severe cardiac amyloidosis: heart transplantation combined with chemotherapy and stem cell transplantation for patients with AL-amyloidosis and heart and liver transplantation for patients with ATTR-amyloidosis. Eur J CardiothoracSurg 2008;33:257-62.
  57. Kristen A, Sack F, Schonland S, Hegenbart U. Staged heart transplantation and chemotherapy as a treatment option in patients with severe cardiac light-chain amyloidosis. Europ J Heart Failure 2009;11:1014-20.
  58. Kpodonu J, Massad M, Caines A, Geha A. Outcome of heart transplantation in patients with amyloid cardiomyopathy. J Heart Lung Transplant 2005;24:1763-65.
  59. Kolstoea S, Mangionea P. Bellottia Trapping of palindromic ligands within native transthyretin prevents amyloid formation. PNAS 2010;107:20483-88.

Supplementary files

Supplementary Files
Action
1. JATS XML
Download

Copyright (c) 2012 Bionika Media

This website uses cookies

You consent to our cookies if you continue to use our website.

About Cookies